Uterine leiomyosarcoma with atypical metastasis post total hysterectomy: Case report
DOI:
https://doi.org/10.35434/rcmhnaaa.2023.162.1694Keywords:
Doxorubicin, Hysterectomy, Ifosfamide, Leiomyoma, Neoplasm MetastasisAbstract
Introduction: Uterine leiomyosarcoma is a rare and highly aggressive sarcoma, which can metastasize most frequently to the lung and liver. Its prognosis is poor, with early total abdominal hysterectomy being the first line treatment. Other alternatives are chemotherapy with regimens of doxorubicin, ifosfamide or gemcitabine, alone or in combination. Case report: We present a 40-year-old Peruvian woman who underwent hysterectomy for suspected leiomyoma; however, pathology revealed a final diagnosis of uterine leiomyosarcoma. She could not be notified due to loss to follow-up. Two years later, she again presented with metastases in the thigh, breast, liver, lungs and scalp. He was given Ifosfamide and Doxorubicin every 21 days for 3 courses, however, due to disease progression, palliative treatment was decided. Finally, he died two months after treatment. Conclusion: A case of uterine leiomyosarcoma with atypical metastasis is presented to promote early and differentiated diagnosis of leiomyoma, low grade leiomyosarcoma and high grade leiomyosarcoma to define the correct treatment.
Downloads
Metrics
References
National Institutes of Health (NIH). SEER Cancer Statistics Review (CSR) 1975-2017 [Internet]. Available from: https://seer.cancer.gov/archive/csr/1975_2017/
Bužinskienė D, Mikėnas S, Drąsutienė G, Mongirdas M. Uterine sarcoma: a clinical case and a literature review. Acta medica Litu. 2019;25(4):206–18. doi: 10.6001/actamedica.v25i4.3931
Bartosch C, Afonso M, Pires-Luis AS, Galaghar A, Guimaraes M, Antunes L, et al. Distant Metastases in Uterine Leiomyosarcomas: The Wide Variety of Body Sites and Time Intervals toMetastatic Relapse. Int J Gynecol Pathol. 2017;36(1):31–41. DOI: 10.1097/PGP.0000000000000284
Rodríguez-Lomba E, Molina-López I, Parra-Blanco V, Suárez-Fernández R, Pulido-Pérez A. Clinical and Histopathologic Findings of Cutaneous Leiomyosarcoma: Correlation with Prognosis in 12 Patients. Actas Dermosifiliogr [Internet]. 2018;109(2):140–7. DOI: 10.1016/j.ad.2017.08.005. Available from: http://dx.doi.org/10.1016/j.ad.2017.08.005
Seagle BLL, Sobecki-Rausch J, Strohl AE, Shilpi A, Grace A, Shahabi S. Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study. Gynecol Oncol [Internet]. 2017;145(1):61–70. DOI: 10.1016/j.ygyno.2017.02.012. Available from: http://dx.doi.org/10.1016/j.ygyno.2017.02.012
Cui RR, Wright JD, Hou JY. Uterine Leiomyosarcoma: a review of recent advances in molecular biology, clinical management and outcome. BJOG. 2017;124(7):1028–37. DOI: 10.1111/1471-0528.14579
Sosa P, Cuadra G, Hidalgo R. Metástasis meníngea de leiomiosarcoma uterino. Reporte de caso y revisión de literatura. Neurocirugia [Internet]. 2018;29(2):103–6. Available from: http://dx.doi.org/10.1016/j.neucir.2017.07.002. DOI: 10.1016/j.neucir.2017.07.002
Köse M, Çelik F, Köse SK, Ariöz DT, Yilmazer M, Tokyol Ç. Recurrent uterine leiomyosarcoma: An atipical location. J Exp Ther Oncol. 2016;11(4):315–8. PMID: 27849343.
O’Brien JM, Brennan DD, Taylor DH, Holloway DP, Hurson B, O’Keane JC, et al. Skeletal muscle metastasis from uterine leiomyosarcoma. Skeletal Radiol. 2004;33(11):655–9. DOI: 10.1007/s00256-004-0787-5
Garcia C, Kubat JS, Fulton RS, Anthony AT, Combs M, Powell CB, et al. Clinical outcomes and prognostic markers in uterine leiomyosarcoma. Int J Gynecol Cancer. 2015;25(4):622–8. DOI: 10.1097/IGC.0000000000000370
Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(May):iv51–67. DOI: 10.1093/annonc/mdy096
Arend RC, Toboni MD, Montgomery AM, Burger RA, Olawaiye AB, Monk BJ, et al. Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm. Oncologist. 2018;23(12):1533–45. DOI: 10.1634/theoncologist.2018-0095
Patel D, Handorf E, Von Mehren M, Martin L, Movva S. Adjuvant chemotherapy in uterine leiomyosarcoma: Trends and factors impacting usage. Sarcoma. 2019;2019. DOI: 10.1155/2019/3561501
Potikul C, Tangjitgamol S, Khunnarong J, Srijaipracharoen S, Thavaramara T, Pataradool K. Uterine sarcoma: Clinical presentation, treatment and survival outcomes in Thailand. Asian Pacific J Cancer Prev. 2016;17(4):1759–67. DOI: 10.7314/apjcp.2016.17.4.1759
DeMulder D, Ascher SM. Uterine leiomyosarcoma: Can MRI differentiate leiomyosarcoma from benign leiomyoma before treatment? Am J Roentgenol. 2018;211(6):1405–15. DOI: 10.2214/AJR.17.19234
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Carlos Quispe-Vicuña, Silvia Villafuerte-Manrique, Carlos Luna-Chuquiña, Silvana Loli-Guevara, Rolig Aliaga
This work is licensed under a Creative Commons Attribution 4.0 International License.
